30 August 2015 - A new NICE adoption resource tool now available to provide practical information and advice on the use of biosimilar versions of infliximab, following guidance published last month.

The NHS staff involved in the production of this resource reported that the use of biosimilars can reduce costs, allowing more treatment with new medicines as long as the appropriate follow-up and monitoring systems are in place to manage risk and patient needs and expectations.

For more details, go to: http://www.nice.org.uk/guidance/htta329

MAESTrO Insight: The PBAC recently published a fact sheet on the use of biosimilars on the PBS.